Centessa Pharmaceuticals develops potential transformative medicines for patients with sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders. The company is advancing its Orexin Receptor 2 Agonist Program as a key therapeutic focus. They leverage an asset-centric approach to pursue novel treatments in these complex disease areas.
Funding
$225M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies often lack precision, leading to off-target effects and limiting their efficacy. Additionally, many patients with sleep-wake disorders and neurological conditions have limited treatment options.
Solution
Centessa Pharmaceuticals is developing targeted immuno-oncology treatments using its LockBody® Technology Platform to enhance the precision of cancer therapies, potentially minimizing off-target effects and improving patient outcomes. The LockBody® platform aims to create conditional antibodies that are activated only in the tumor microenvironment. Centessa is also advancing its Orexin Receptor 2 Agonist Program to provide new treatment options for sleep-wake disorders, neurological, neurodegenerative, and psychiatric conditions. Their approach focuses on developing potential first-in-class or best-in-class medicines, addressing high unmet needs and improving standards of care.
Target Audience
The primary target audience includes patients with cancer and individuals suffering from sleep-wake disorders, neurological, neurodegenerative, and psychiatric conditions, as well as the healthcare professionals who treat them.
Features
- LockBody® Technology Platform: Develops conditional antibodies for targeted immuno-oncology.
- Orexin Receptor 2 Agonist Program: Creates novel treatments for sleep-wake and neurological disorders.
- Data-driven decision-making: Utilizes data to rapidly progress programs through development.
- Focus on first-in-class/best-in-class medicines.